Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
08 Agosto 2024 - 3:05PM
Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable,
commercial-stage biotechnology company with clinical development
programs focusing on a variety of chronic organ diseases, today
announced the appointment of David M. Epstein, Ph.D., to Gyre’s
Board of Directors (the “Board”), effective August 6, 2024. Dr.
Epstein will serve as a member of the Audit Committee of the Board
and as member of the Compensation Committee of the Board.
“We are thrilled to welcome David to the Gyre Board,” said Han
Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. “His
extensive global experience in biotech companies across the U.S.
and Asia will be instrumental to Gyre as we advance our robust
pipeline of clinical and pre-clinical assets forward.”
“I am delighted to join Gyre’s Board and to work with the
company as it continues to advance novel therapies for fibrotic
diseases,” said Dr. Epstein. “I look forward to supporting Gyre as
it continues to develop its global therapeutic pipeline.”
Dr. Epstein is a co-founder of PairX Bio Pte. Ltd., a
Singapore-based biotechnology company that is developing
next-generation cancer-selective biologics, where he currently
serves as director, President and Chief Executive Officer. Dr.
Epstein co-founded and served as President and Chief Executive
Officer of Black Diamond Therapeutics (Nasdaq: BDTX), leading the
company through its January 2020 IPO and clinical proof-of-concept
of its EFGR MasterKey inhibitor in 2023. Prior to Black Diamond,
Dr. Epstein was Vice Dean, Innovation & Entrepreneurship and
Associate Professor at Duke-NUS Medical School in Singapore, and
prior to that he served as Chief Scientific Officer of OSI
Pharmaceuticals (“OSI”), which was acquired by Astellas Pharma for
over $4 billion in 2010. Before his time at OSI, Dr. Epstein was a
scientific founder and director at Archemix Corp., where he
developed avacincaptad pegol (Izervay™), an anti-C5 aptamer for
treatment of geographic atrophy secondary to age-related macular
degeneration. Izervay™ was acquired by Iveric Bio and sold to
Astellas Pharma Inc. for $5.9 billion in 2023.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company
headquartered in San Diego, CA, with a primary focus on the
development and commercialization of F351 (Hydronidone) for the
treatment of NASH-associated fibrosis in the U.S. Gyre’s
development strategy for F351 in NASH is based on the company’s
experience in NASH rodent model mechanistic studies and CHB-induced
liver fibrosis clinical studies. Gyre is also advancing a diverse
pipeline in the PRC through its indirect controlling interest in
Gyre Pharmaceuticals, including ETUARY therapeutic expansions,
F573, F528, and F230.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995, which statements are
subject to substantial risks and uncertainties and are based on
estimates and assumptions. All statements, other than statements of
historical facts included in this press release, are
forward-looking statements, including statements concerning:
expectations regarding Gyre’s research and development efforts,
expectations regarding future product sales, and Gyre’s business
strategies. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “objective,”
“intend,” “should,” “could,” “can,” “would,” “expect,” “believe,”
“design,” “estimate,” “predict,” “potential,” “plan” or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. These statements reflect
Gyre’s plans, estimates, and expectations, as of the date of this
press release. These statements involve known and unknown risks,
uncertainties and other factors that could cause Gyre’s actual
results to differ materially from the forward-looking statements
expressed or implied in this press release, including without
limitation: Gyre’s ability to execute on its clinical development
strategies; positive results from a clinical trial may not
necessarily be predictive of the results of future or ongoing
clinical trials; the timing or likelihood of regulatory filings and
approvals; competition from competing products; the impact of
general economic, health, industrial or political conditions in the
United States or internationally; the sufficiency of Gyre’s capital
resources and its ability to raise additional capital. Additional
risks and factors are identified under “Risk Factors” in Gyre’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed on March 27, 2024, and subsequent reports filed with the
Securities and Exchange Commission.
Gyre expressly disclaims any obligation to update any
forward-looking statements whether as a result of new information,
future events or otherwise, except as required by law.
For Investors:
Stephen Jasper
stephen@gilmartinir.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024